HK1223096A1 - 用作 信號通路抑制劑的咪唑並噠嗪 - Google Patents
用作 信號通路抑制劑的咪唑並噠嗪Info
- Publication number
- HK1223096A1 HK1223096A1 HK16111240.7A HK16111240A HK1223096A1 HK 1223096 A1 HK1223096 A1 HK 1223096A1 HK 16111240 A HK16111240 A HK 16111240A HK 1223096 A1 HK1223096 A1 HK 1223096A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- par
- imidazopyridazines
- inhibitors
- useful
- signaling pathway
- Prior art date
Links
- 101100406879 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) par-2 gene Proteins 0.000 title 2
- 150000005233 imidazopyridazines Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 230000019491 signal transduction Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361882173P | 2013-09-25 | 2013-09-25 | |
US201361901617P | 2013-11-08 | 2013-11-08 | |
PCT/US2014/057390 WO2015048245A1 (en) | 2013-09-25 | 2014-09-25 | Imidazopyridazines useful as inhibitors of the par-2 signaling pathway |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1223096A1 true HK1223096A1 (zh) | 2017-07-21 |
Family
ID=52293160
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK16111240.7A HK1223096A1 (zh) | 2013-09-25 | 2016-09-23 | 用作 信號通路抑制劑的咪唑並噠嗪 |
HK16113758A HK1225386A1 (zh) | 2013-09-25 | 2016-12-01 | 用作par-2信號傳導途徑抑制劑的咪唑並噠嗪類 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK16113758A HK1225386A1 (zh) | 2013-09-25 | 2016-12-01 | 用作par-2信號傳導途徑抑制劑的咪唑並噠嗪類 |
Country Status (12)
Country | Link |
---|---|
US (2) | US10030024B2 (zh) |
EP (1) | EP3049418A1 (zh) |
JP (1) | JP2016531864A (zh) |
KR (1) | KR20160060120A (zh) |
CN (1) | CN105683192A (zh) |
AU (2) | AU2014326596B2 (zh) |
BR (1) | BR112016006151A2 (zh) |
CA (1) | CA2924690A1 (zh) |
HK (2) | HK1223096A1 (zh) |
IL (1) | IL244739A0 (zh) |
TW (1) | TW201602109A (zh) |
WO (1) | WO2015048245A1 (zh) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015048245A1 (en) | 2013-09-25 | 2015-04-02 | Vertex Pharmaceuticals Incorporated | Imidazopyridazines useful as inhibitors of the par-2 signaling pathway |
WO2017093180A1 (de) | 2015-12-01 | 2017-06-08 | Bayer Cropscience Aktiengesellschaft | Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel |
ES2909709T3 (es) * | 2016-05-12 | 2022-05-10 | Heptares Therapeutics Ltd | Inhibidores del receptor 2 activado por proteasa |
CA3024719A1 (en) * | 2016-05-20 | 2017-11-23 | Takeda Pharmaceutical Company Limited | Treatment of pain |
EP3497102B1 (de) | 2016-08-15 | 2022-12-07 | Bayer CropScience Aktiengesellschaft | Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel |
BR112019001968A2 (pt) | 2016-08-31 | 2019-05-07 | Eisai R&D Management Co., Ltd. | composto pirazolo[1,5-a]pirimidina |
WO2018057588A1 (en) * | 2016-09-21 | 2018-03-29 | Vertex Pharmaceuticals Incorporated | Furo[3,2-b]pyridine compounds useful as inhibitors of the par-2 signaling pathway |
US11690847B2 (en) | 2016-11-30 | 2023-07-04 | Case Western Reserve University | Combinations of 15-PGDH inhibitors with corticosteroids and/or TNF inhibitors and uses thereof |
WO2018145080A1 (en) * | 2017-02-06 | 2018-08-09 | Case Western Reserve University | Compositions and methods of modulating short-chain dehydrogenase activity |
AU2018344370C1 (en) | 2017-10-04 | 2023-04-27 | Bayer Aktiengesellschaft | Derivatives of heterocyclic compounds as pest control agents |
JP2021508692A (ja) * | 2017-12-20 | 2021-03-11 | 武田薬品工業株式会社 | プロテアーゼ活性化受容体−2の阻害剤 |
AU2019224410A1 (en) * | 2018-02-26 | 2020-07-09 | Eisai R&D Management Co., Ltd. | Salt of pyrazolo[1,5-a]pyrimidine compound and crystals thereof |
JP2021515783A (ja) | 2018-03-12 | 2021-06-24 | バイエル・アクチエンゲゼルシヤフト | 害虫防除剤としての縮合二環式ヘテロ環式誘導体 |
KR20210005081A (ko) | 2018-04-20 | 2021-01-13 | 바이엘 악티엔게젤샤프트 | 해충 방제제로서의 헤테로시클렌 유도체 |
WO2020201572A1 (en) | 2019-04-05 | 2020-10-08 | Université De Bretagne Occidentale | Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning |
WO2022117882A2 (en) | 2020-12-03 | 2022-06-09 | Domain Therapeutics | Novel par-2 inhibitors |
EP4308577A1 (en) | 2021-03-17 | 2024-01-24 | F. Hoffmann-La Roche AG | New thiadiazolopyrimidone derivatives |
WO2023233033A1 (en) | 2022-06-03 | 2023-12-07 | Domain Therapeutics | Novel par-2 inhibitors |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA01009871A (es) * | 1999-04-01 | 2002-04-24 | Pfizer Prod Inc | Aminopiridinas como inhibidores de la sorbitol deshidrogenasa. |
US7696168B2 (en) | 2000-04-21 | 2010-04-13 | Tufts Medical Center, Inc. | G protein coupled receptor agonists and antagonists and methods of activating and inhibiting G protein coupled receptors using the same |
EP2336169A1 (en) | 2000-04-21 | 2011-06-22 | New England Medical Center Hospital | G protein coupled receptor (GPCR) agonists and antagonists and methods of activating and inhibiting GPCR using the same |
ATE541847T1 (de) * | 2001-11-01 | 2012-02-15 | Icagen Inc | Pyrazolopyrimidine als natriumkanalblocker |
JP2003286171A (ja) * | 2002-03-28 | 2003-10-07 | Sumitomo Pharmaceut Co Ltd | Par阻害剤 |
GB0213286D0 (en) | 2002-06-10 | 2002-07-24 | Univ Edinburgh | Par-2-Activating peptide derivative and pharmaceutical composition using the same |
JP2004170323A (ja) * | 2002-11-22 | 2004-06-17 | Sumitomo Pharmaceut Co Ltd | 皮膚疾患治療剤のスクリーニング方法 |
JPWO2005030773A1 (ja) * | 2003-09-26 | 2006-12-07 | 大日本住友製薬株式会社 | 新規ピラゾロピリミジン誘導体 |
US8268789B2 (en) | 2004-09-30 | 2012-09-18 | Kowa Company, Ltd. | PAR-2 antagonists |
WO2006070780A1 (ja) | 2004-12-28 | 2006-07-06 | Kowa Company, Ltd. | Par-2アゴニスト |
US8133864B2 (en) | 2005-03-29 | 2012-03-13 | Kowa Company, Ltd. | PAR-2 agonist |
US20080318960A1 (en) | 2005-05-26 | 2008-12-25 | Ethan Burstein | PAR2-modulating compounds and their use |
US20070123508A1 (en) | 2005-05-27 | 2007-05-31 | Roger Olsson | PAR2-modulating compounds and their use |
WO2007076055A2 (en) | 2005-12-22 | 2007-07-05 | Entremed, Inc. | Compositions and methods comprising proteinase activated receptor antagonists |
US7888482B2 (en) | 2006-02-10 | 2011-02-15 | Amgen Inc. | Antibodies that bind PAR-2 |
CL2008001887A1 (es) | 2007-06-29 | 2008-10-03 | Amgen Inc | Proteinas de union a antigeno que se unen al receptor activado por proteasas 2 (par-2); acido nucleico que las codifica; vector y celula huesped; metodo de produccion; y composicion que las comprende. |
US9044510B2 (en) | 2007-11-01 | 2015-06-02 | Washington University | Compositions and methods for treating pruritus |
AR070911A1 (es) | 2008-03-19 | 2010-05-12 | Regeneron Pharma | Uso de antagonistas del receptor par2 activado con proteasa |
CA2733041A1 (en) | 2008-08-05 | 2010-02-11 | Boehringer Ingelheim International Gmbh | Effectors of par-2 activation and their use in the modulation of inflammation |
US8852569B2 (en) | 2008-08-28 | 2014-10-07 | The General Hospital Corporation | Prevention and treatment of itch with cysteine protease inhibition |
AU2010233089B2 (en) | 2009-04-10 | 2016-05-26 | Tufts Medical Center, Inc. | Par-1 activation by metalloproteinase-1 (MMP-1) |
EP2427205A2 (en) | 2009-05-04 | 2012-03-14 | INSERM - Institut National de la Santé et de la Recherche Médicale | Par2 agonists for use in the treatment or prevention of influenza virus type a infections |
US20120107329A1 (en) | 2009-06-10 | 2012-05-03 | University Of Maryland, Baltimore | EGFR and PAR2 Regulation of Intestinal Permeability |
JO3246B1 (ar) | 2009-09-09 | 2018-03-08 | Regeneron Pharma | اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري |
EP2335717A1 (en) | 2009-11-16 | 2011-06-22 | Institut National De La Recherche Agronomique | PAR-1 antagonists for use in the treatment or prevention of influenza virus type a infections |
US8927503B2 (en) | 2010-07-28 | 2015-01-06 | The University Of Queensland | Modulations of protease activated receptors |
PL2610255T3 (pl) | 2010-08-25 | 2016-08-31 | Neopharm Co Ltd | Związki 1H-benzo[d]imidazol-5-ilowe i kompozycja do leczenia chorób zapalnych |
FR2969657B1 (fr) | 2010-12-22 | 2014-02-07 | Fabre Pierre Dermo Cosmetique | Nouvelle bacterie et extraits de ladite bacterie et leur utilisation en dermatologie |
US9745347B2 (en) | 2010-12-30 | 2017-08-29 | Hadasit Medical Research Services And Development Ltd. | PAR1 and PAR2 c-tail peptides and peptide mimetics |
GB201101517D0 (en) | 2011-01-28 | 2011-03-16 | Proximagen Ltd | Receptor antagonists |
WO2012139137A2 (en) | 2011-04-08 | 2012-10-11 | Tufts Medical Center, Inc. | Pepducin design and use |
KR101412119B1 (ko) | 2011-09-29 | 2014-06-27 | 주식회사 펩트론 | 생리적 안정성을 증가시킨 par―2 활성화 펩타이드 및 이를 함유하는 약제학적 조성물 |
WO2013064583A1 (en) | 2011-11-04 | 2013-05-10 | Lipotec, S.A. | Peptides which inhibit activated receptors and their use in cosmetic or pharmaceutical compositions |
US9868763B2 (en) | 2011-11-07 | 2018-01-16 | The University Of Queensland | Modulators of protease activated receptors |
CA2923595C (en) | 2012-05-18 | 2020-07-14 | Tufts Medical Center, Inc. | Polypeptide and lipophilic moiety conjugate compositions, formulations, and uses related thereto |
GB201213700D0 (en) | 2012-08-01 | 2012-09-12 | Proximagen Ltd | Receptor antagnists II |
US9808505B2 (en) | 2013-03-08 | 2017-11-07 | Board Of Regents, The University Of Texas System | Suppression of malignant mesothelioma by overexpression or stimulation of endothelial protein C receptors (EPCR) |
WO2014173859A2 (en) | 2013-04-22 | 2014-10-30 | Institut National De La Recherche Agronomique | Par-4 antagonists for use in the treatment or prevention of influenza virus type a infections |
WO2015048245A1 (en) | 2013-09-25 | 2015-04-02 | Vertex Pharmaceuticals Incorporated | Imidazopyridazines useful as inhibitors of the par-2 signaling pathway |
US9790506B2 (en) | 2013-10-02 | 2017-10-17 | The Regents Of The University Of California | Diagnostic and screening methods for atopic dermatitis |
WO2015117956A1 (en) | 2014-02-04 | 2015-08-13 | Celltrend Gmbh | Diagnosis of cancer by detecting auto-antibodies against par1 |
JP5719050B2 (ja) | 2014-02-28 | 2015-05-13 | ザ プロクター アンド ギャンブルカンパニー | 角化細胞のpar2活性化を阻害するための組成物及び方法 |
US20160000791A1 (en) | 2014-07-07 | 2016-01-07 | Mayo Foundation For Medical Education And Research | Par1 modulation to alter myelination |
WO2016005369A1 (en) | 2014-07-08 | 2016-01-14 | Celltrend Gmbh | Par2 antibodies for diagnosis of graft intolerance of a liver transplant |
WO2016138132A1 (en) | 2015-02-25 | 2016-09-01 | The Trustees Of Columbia University In The City Of New York | Dipeptidyl peptidase-iv(dpp4) inhibitors, methods and compositions for suppressing adipose tissue inflammation |
-
2014
- 2014-09-25 WO PCT/US2014/057390 patent/WO2015048245A1/en active Application Filing
- 2014-09-25 AU AU2014326596A patent/AU2014326596B2/en not_active Ceased
- 2014-09-25 EP EP14824596.2A patent/EP3049418A1/en not_active Withdrawn
- 2014-09-25 CN CN201480058774.8A patent/CN105683192A/zh active Pending
- 2014-09-25 BR BR112016006151A patent/BR112016006151A2/pt not_active Application Discontinuation
- 2014-09-25 KR KR1020167010382A patent/KR20160060120A/ko not_active Application Discontinuation
- 2014-09-25 TW TW103133360A patent/TW201602109A/zh unknown
- 2014-09-25 CA CA2924690A patent/CA2924690A1/en not_active Abandoned
- 2014-09-25 JP JP2016516947A patent/JP2016531864A/ja active Pending
-
2016
- 2016-03-23 IL IL244739A patent/IL244739A0/en unknown
- 2016-03-25 US US15/081,076 patent/US10030024B2/en not_active Expired - Fee Related
- 2016-09-23 HK HK16111240.7A patent/HK1223096A1/zh unknown
- 2016-12-01 HK HK16113758A patent/HK1225386A1/zh unknown
-
2018
- 2018-06-20 US US16/013,523 patent/US20190119282A1/en not_active Abandoned
-
2019
- 2019-03-06 AU AU2019201532A patent/AU2019201532A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20160311825A1 (en) | 2016-10-27 |
US10030024B2 (en) | 2018-07-24 |
CN105683192A (zh) | 2016-06-15 |
HK1225386A1 (zh) | 2017-09-08 |
WO2015048245A1 (en) | 2015-04-02 |
AU2014326596B2 (en) | 2018-12-13 |
JP2016531864A (ja) | 2016-10-13 |
CA2924690A1 (en) | 2015-04-02 |
TW201602109A (zh) | 2016-01-16 |
EP3049418A1 (en) | 2016-08-03 |
AU2014326596A1 (en) | 2016-04-07 |
KR20160060120A (ko) | 2016-05-27 |
IL244739A0 (en) | 2016-04-21 |
BR112016006151A2 (pt) | 2017-08-01 |
AU2019201532A1 (en) | 2019-03-28 |
US20190119282A1 (en) | 2019-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1225386A1 (zh) | 用作par-2信號傳導途徑抑制劑的咪唑並噠嗪類 | |
ZA201800854B (en) | Novel bicyclic bromodomain inhibitors | |
HK1212691A1 (zh) | 犬尿氨酸途徑的抑制劑 | |
IL265496A (en) | bace1 inhibitors | |
HK1211578A1 (zh) | 作為 激酶抑制劑的酰氨基咪唑並噠嗪 | |
HK1216531A1 (zh) | 新的抑制劑 | |
HK1217492A1 (zh) | 作爲刺猬信號通路抑制劑的雜環化合物 | |
HUE046914T2 (hu) | N-piridinil-acetamid-származékok, mint a WNT jelátviteli út inhibitorai | |
GB201314578D0 (en) | Bicyclic inhibitors | |
HK1223367A1 (zh) | 新型 抑制劑 | |
EP3632467C0 (en) | INHIBITORS OF COMPLEMENT FACTOR H | |
HK1222339A1 (zh) | 金屬-β-內酰胺酶的抑制劑 | |
IL240763B (en) | The halopyrazoles as thrombin inhibitors | |
IL247366A0 (en) | Inhibitors of wnt signaling pathways | |
HK1222386A1 (zh) | 作爲詹納斯激酶的抑制劑的 -氰基甲基酰胺 |